JP2020534352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534352A5 JP2020534352A5 JP2020536495A JP2020536495A JP2020534352A5 JP 2020534352 A5 JP2020534352 A5 JP 2020534352A5 JP 2020536495 A JP2020536495 A JP 2020536495A JP 2020536495 A JP2020536495 A JP 2020536495A JP 2020534352 A5 JP2020534352 A5 JP 2020534352A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- terminus
- epitope
- cell
- cell mmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 103
- 229920001184 polypeptide Polymers 0.000 claims description 101
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 101
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 74
- 235000001014 amino acid Nutrition 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 18
- 230000021615 conjugation Effects 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 18
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 18
- 230000000735 allogeneic effect Effects 0.000 claims description 10
- -1 CD86 Proteins 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 102000005262 Sulfatase Human genes 0.000 claims description 7
- 108060007951 sulfatase Proteins 0.000 claims description 7
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000043129 MHC class I family Human genes 0.000 claims description 4
- 108091054437 MHC class I family Proteins 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 claims description 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 claims description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 2
- 101000994437 Homo sapiens Protein jagged-1 Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims description 2
- 102100034980 ICOS ligand Human genes 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 2
- 102100032702 Protein jagged-1 Human genes 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 150000002482 oligosaccharides Polymers 0.000 claims description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 claims description 2
- 235000016491 selenocysteine Nutrition 0.000 claims description 2
- 229940055619 selenocysteine Drugs 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims 11
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555559P | 2017-09-07 | 2017-09-07 | |
| US62/555,559 | 2017-09-07 | ||
| US201762609082P | 2017-12-21 | 2017-12-21 | |
| US62/609,082 | 2017-12-21 | ||
| US201862615402P | 2018-01-09 | 2018-01-09 | |
| US62/615,402 | 2018-01-09 | ||
| PCT/US2018/049803 WO2019051127A1 (en) | 2017-09-07 | 2018-09-06 | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020534352A JP2020534352A (ja) | 2020-11-26 |
| JP2020534352A5 true JP2020534352A5 (enExample) | 2021-10-28 |
Family
ID=65634577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020536495A Pending JP2020534352A (ja) | 2017-09-07 | 2018-09-06 | コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12006348B2 (enExample) |
| EP (1) | EP3679064A4 (enExample) |
| JP (1) | JP2020534352A (enExample) |
| KR (1) | KR20200064085A (enExample) |
| CN (1) | CN111315768A (enExample) |
| AU (1) | AU2018327224A1 (enExample) |
| CA (1) | CA3074839A1 (enExample) |
| IL (1) | IL273091A (enExample) |
| TW (1) | TW201920249A (enExample) |
| WO (1) | WO2019051127A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202006338UA (en) * | 2014-06-18 | 2020-08-28 | Albert Einstein College Medicine Inc | Syntac polypeptides and uses thereof |
| CN109475628A (zh) * | 2016-05-18 | 2019-03-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| AU2017379900B2 (en) | 2016-12-22 | 2024-12-05 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| EP3596118B1 (en) | 2017-03-15 | 2024-08-21 | Cue Biopharma, Inc. | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| WO2019051127A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| TWI856047B (zh) * | 2018-12-19 | 2024-09-21 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| WO2020132368A1 (en) * | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| GB201904328D0 (en) * | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| CN118852456A (zh) * | 2019-05-29 | 2024-10-29 | Cue生物制药股份有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| EP3986448A4 (en) * | 2019-06-19 | 2023-07-12 | Cue Biopharma, Inc. | MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF |
| CN110684081A (zh) * | 2019-09-02 | 2020-01-14 | 天益健康科学研究院（镇江）有限公司 | 一种编码分泌型多肽氨基酸的重组溶瘤新城疫病毒及其制备方法 |
| EP4030897A4 (en) * | 2019-09-20 | 2023-10-18 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| JP2023500574A (ja) * | 2019-10-23 | 2023-01-10 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節性キメラ分子及びその使用方法 |
| US20210188934A1 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| WO2021168388A1 (en) * | 2020-02-21 | 2021-08-26 | 3T Biosciences, Inc. | Yeast display libraries, associated compositions, and associated methods of use |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| WO2021195411A1 (en) * | 2020-03-25 | 2021-09-30 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| JP2023525822A (ja) * | 2020-05-12 | 2023-06-19 | エルジー・ケム・リミテッド | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
| EP4149534A4 (en) * | 2020-05-12 | 2024-09-04 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF |
| WO2021242935A1 (en) * | 2020-05-26 | 2021-12-02 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes and methods of use thereof |
| US20230218731A1 (en) * | 2020-05-26 | 2023-07-13 | Cue Biopharma, Inc. | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| WO2022099156A2 (en) * | 2020-11-06 | 2022-05-12 | Cue Biopharma, Inc. | T-cell modulatory polypeptides with conjugation sites and methods of use thereof |
| WO2022197971A1 (en) * | 2021-03-19 | 2022-09-22 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| CN117222421A (zh) * | 2021-03-19 | 2023-12-12 | Cue生物制药股份有限公司 | T细胞调节多肽和其使用方法 |
| EP4416175A4 (en) * | 2021-10-12 | 2025-08-13 | Adoc Ssf Llc | COMPOSITIONS AND METHODS FOR ISOLATING T CELL RECEPTORS (TCR) AND CELLS EXPRESSING THEM |
| WO2025101521A1 (en) * | 2023-11-06 | 2025-05-15 | Cue Biopharma, Inc. | Methods for treating hpv16-associated cancers |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1548716A (en) | 1924-10-02 | 1925-08-04 | Fournier Santiago Emilien | Process for the manufacture of artificial freestone |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| US6682741B1 (en) | 1998-06-10 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | β2 microglobulin fusion proteins and high affinity variants |
| US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| AU2000277350A1 (en) | 2000-09-29 | 2002-04-15 | Steven J. Bark | Labeled peptides, and processes and intermediates useful for their preparation |
| WO2002074331A2 (en) * | 2001-03-19 | 2002-09-26 | Isis Innovation Limited | Mutated mhc molecules for use in immune suppression |
| EP1490483B1 (en) | 2001-04-19 | 2015-06-03 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| WO2005081716A2 (en) | 2003-11-24 | 2005-09-09 | The Johns Hopkins University | DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) |
| GB0329146D0 (en) | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
| CA2611946C (en) | 2005-06-20 | 2013-04-16 | Cadila Healthcare Limited | Expression vector and methods of producing high levels of proteins |
| US7521195B1 (en) | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| EP1996937A4 (en) | 2006-03-06 | 2009-04-08 | Amunix Inc | GENETIC PACKS AND USES THEREOF |
| US8992937B2 (en) | 2006-08-28 | 2015-03-31 | Washington University | Disulfide trap MHC class I molecules and uses therefor |
| BRPI0815416A2 (pt) | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| CA2735006A1 (en) * | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| US20110318380A1 (en) | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
| US20120021484A1 (en) * | 2008-10-22 | 2012-01-26 | Biogen Idec Ma Inc. | Recombinant FcRn and Variants Thereof for Purification of Fc-Containing Fusion Proteins |
| PT2367561E (pt) | 2008-11-30 | 2015-10-23 | Immusant Inc | Composições e métodos para o tratamento da doença celíaca |
| WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
| WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| WO2012037551A2 (en) | 2010-09-17 | 2012-03-22 | Irx Therapeutics, Inc. | Primary cell-derived biologic and wt1 synthetic long peptide vaccine |
| US20120141537A1 (en) | 2010-11-18 | 2012-06-07 | Pease Larry R | Enhancing t cell activation using altered mhc-peptide ligands |
| WO2012088446A1 (en) * | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| US9540438B2 (en) | 2011-01-14 | 2017-01-10 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof |
| AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
| US20140134195A1 (en) | 2011-04-20 | 2014-05-15 | University Of Washington Through Its Center For Commercialization | Beta-2 microglobulin-deficient cells |
| WO2013022091A1 (ja) | 2011-08-11 | 2013-02-14 | 小野薬品工業株式会社 | Ｐｄ－１アゴニストからなる自己免疫疾患治療剤 |
| WO2013030620A2 (de) | 2011-08-30 | 2013-03-07 | Jacobs University Bremen Ggmbh | Gen codiert für ein mhc-klasse-i-molekül, plasmid, expressionssystem protein, multimer, reagenz und kit zum analysieren einer t-zellen-frequenz |
| AU2013207669C1 (en) | 2012-01-13 | 2018-05-31 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| SG11201408161RA (en) | 2012-06-08 | 2015-01-29 | Sutro Biopharma Inc | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| EP3135690A1 (en) | 2012-06-26 | 2017-03-01 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| KR102165464B1 (ko) * | 2012-07-19 | 2020-10-14 | 레드우드 바이오사이언스 인코포레이티드 | Cd22에 대해 특이적인 항체 및 이들의 사용 방법 |
| US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| CN105121715B (zh) | 2012-12-11 | 2018-10-26 | 艾伯特叶史瓦大学爱因斯坦医学院 | 高通量受体:配体鉴定方法 |
| SG11201605632SA (en) | 2014-01-21 | 2016-08-30 | Einstein Coll Med | Cellular platform for rapid and comprehensive t-cell immunomonitoring |
| SI3134127T1 (sl) | 2014-04-25 | 2020-06-30 | Rinat Neuroscience Corp. | Konjugati zdravil s protitelesi z visoko stopnjo zdravila |
| KR102557615B1 (ko) | 2014-06-06 | 2023-07-20 | 레드우드 바이오사이언스 인코포레이티드 | 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법 |
| SG10202006338UA (en) | 2014-06-18 | 2020-08-28 | Albert Einstein College Medicine Inc | Syntac polypeptides and uses thereof |
| EP3286222A4 (en) | 2015-03-23 | 2018-08-08 | The Johns Hopkins University | Hla-restricted epitopes encoded by somatically mutated genes |
| US10472412B2 (en) | 2015-03-25 | 2019-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific multivalent fusion proteins |
| TWI716405B (zh) | 2015-05-07 | 2021-01-21 | 美商艾吉納斯公司 | 抗ox40抗體及其使用方法 |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| EP3423108A4 (en) * | 2016-03-02 | 2019-10-02 | Cue Biopharma, Inc. | T CELL MODULATING MULTIPLE POLYPEPTIDES AND METHOD OF USE THEREOF |
| CA3014466A1 (en) | 2016-03-03 | 2017-09-08 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| RS67172B1 (sr) | 2016-03-31 | 2025-09-30 | Biontech Us Inc | Neoantigeni i postupci za njihovu upotrebu |
| KR20240115933A (ko) * | 2016-05-04 | 2024-07-26 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| CA3022331A1 (en) | 2016-05-18 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof |
| CN109475628A (zh) | 2016-05-18 | 2019-03-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| DE102016222109A1 (de) | 2016-11-10 | 2018-05-17 | Robert Bosch Gmbh | Brennstoffzellensystem |
| AU2017379900B2 (en) | 2016-12-22 | 2024-12-05 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3596118B1 (en) | 2017-03-15 | 2024-08-21 | Cue Biopharma, Inc. | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer |
| EP3595706A1 (en) | 2017-03-17 | 2020-01-22 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| WO2019051127A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| WO2019051126A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF |
| IL297361B2 (en) | 2017-09-07 | 2024-07-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| JP2021500855A (ja) | 2017-09-07 | 2021-01-14 | キュー バイオファーマ， インコーポレイテッド | 抗原提示ポリペプチドおよびその使用方法 |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| SG11202009761YA (en) | 2018-04-02 | 2020-10-29 | Pact Pharma Inc | Peptide-mhc compacts |
| WO2020132366A2 (en) | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| BR112021011838A2 (pt) | 2018-12-19 | 2021-08-31 | Cue Biopharma, Inc. | Peptídeos multiméricos moduladores de células t e métodos de uso destes |
| WO2020132136A1 (en) | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2020132365A2 (en) | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| WO2020132135A1 (en) | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2020132368A1 (en) | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| TWI856047B (zh) | 2018-12-19 | 2024-09-21 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| CN113795263A (zh) | 2019-02-20 | 2021-12-14 | 鲁比厄斯治疗法股份有限公司 | 包含可负载抗原呈递多肽的工程化红系细胞及使用方法 |
| EP3935080A4 (en) | 2019-03-06 | 2023-04-05 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3935079A4 (en) | 2019-03-06 | 2023-03-22 | Cue Biopharma, Inc. | T LYMPHOCYTE MODULATOR ANTIGEN PRESENTING POLYPEPTIDES AND METHODS OF USE THEREOF |
| CN118852456A (zh) | 2019-05-29 | 2024-10-29 | Cue生物制药股份有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| EP3986448A4 (en) | 2019-06-19 | 2023-07-12 | Cue Biopharma, Inc. | MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF |
| EP4030897A4 (en) | 2019-09-20 | 2023-10-18 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| US20230265134A1 (en) | 2019-09-30 | 2023-08-24 | Adimab, Llc | Ch1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same |
| JP2023500574A (ja) | 2019-10-23 | 2023-01-10 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節性キメラ分子及びその使用方法 |
| AU2020369573A1 (en) | 2019-10-23 | 2022-03-24 | Cue Biopharma, Inc. | Modified cytotoxic T cells and methods of use thereof |
| WO2021195108A1 (en) | 2020-03-24 | 2021-09-30 | Cue Biopharma, Inc. | T cell modulatory polypeptides and methods of use thereof |
| WO2021195411A1 (en) | 2020-03-25 | 2021-09-30 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| EP4149534A4 (en) | 2020-05-12 | 2024-09-04 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF |
| WO2021242935A1 (en) | 2020-05-26 | 2021-12-02 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes and methods of use thereof |
| WO2022015880A2 (en) | 2020-07-14 | 2022-01-20 | Cue Biopharma, Inc. | T-cell modulatory polypeptides with conjugation sites and methods of use thereof |
| WO2022056015A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| US20230414777A1 (en) | 2020-11-06 | 2023-12-28 | Cue Biopharma, Inc. | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof |
| WO2022099156A2 (en) | 2020-11-06 | 2022-05-12 | Cue Biopharma, Inc. | T-cell modulatory polypeptides with conjugation sites and methods of use thereof |
| WO2022119958A1 (en) | 2020-12-02 | 2022-06-09 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN117222421A (zh) | 2021-03-19 | 2023-12-12 | Cue生物制药股份有限公司 | T细胞调节多肽和其使用方法 |
| WO2022197971A1 (en) | 2021-03-19 | 2022-09-22 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| CA3216278A1 (en) | 2021-04-21 | 2022-10-27 | Iii Ronald D. Seidel | Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof |
| WO2022226073A1 (en) | 2021-04-21 | 2022-10-27 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory polypeptides and methods of use thereof |
| AU2022261908A1 (en) | 2021-04-21 | 2023-10-05 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| EP4426721A4 (en) | 2021-11-04 | 2025-10-08 | Cue Biopharma Inc | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF |
-
2018
- 2018-09-06 WO PCT/US2018/049803 patent/WO2019051127A1/en not_active Ceased
- 2018-09-06 JP JP2020536495A patent/JP2020534352A/ja active Pending
- 2018-09-06 KR KR1020207009953A patent/KR20200064085A/ko not_active Withdrawn
- 2018-09-06 AU AU2018327224A patent/AU2018327224A1/en not_active Abandoned
- 2018-09-06 TW TW107131342A patent/TW201920249A/zh unknown
- 2018-09-06 CN CN201880071636.1A patent/CN111315768A/zh active Pending
- 2018-09-06 CA CA3074839A patent/CA3074839A1/en active Pending
- 2018-09-06 EP EP18853566.0A patent/EP3679064A4/en active Pending
-
2020
- 2020-03-05 IL IL273091A patent/IL273091A/en unknown
- 2020-03-06 US US16/812,125 patent/US12006348B2/en active Active
-
2024
- 2024-05-06 US US18/656,531 patent/US20240409606A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534352A5 (enExample) | ||
| TWI648401B (zh) | 生長分化因子１５（ｇｄｆ－１５）構築體 | |
| JP5885885B2 (ja) | Ｗｔ１抗原ペプチドコンジュゲートワクチン | |
| AU2016232659B2 (en) | A novel complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of colorectal cancer | |
| JP6355563B2 (ja) | Ｘｔｅｎ共役組成物およびそれを製造する方法 | |
| WO2020132368A4 (en) | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof | |
| CN109963585B (zh) | 包括细胞穿透肽、多表位和tlr肽激动剂的用于治疗癌症的融合物 | |
| WO2019051126A4 (en) | Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof | |
| ES2400249T3 (es) | Vacunas recombinantes y utilización de las mismas | |
| EP3429618B1 (en) | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine | |
| Falnes et al. | Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment | |
| JP7090335B2 (ja) | 治療剤に対する免疫応答を除去するための改善された方法及び化合物 | |
| WO2020132366A4 (en) | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof | |
| JP2021500855A5 (enExample) | ||
| JP2017519491A5 (enExample) | ||
| JPH04502850A (ja) | アドヘゾン変異体 | |
| JP2015526434A (ja) | ペプチド−デンドリマーコンジュゲート及びその使用 | |
| JP2020143084A (ja) | 治療目的のための抗体−ウレアーゼコンジュゲート | |
| CN102573902A (zh) | 用于基于亚单位的痘病毒疫苗的包含痘病毒衍生肽和针对抗原呈递细胞的抗体的免疫偶联物 | |
| Lühmann et al. | Biodistribution of site-specific PEGylated fibroblast growth factor-2 | |
| HRP20140886T1 (hr) | MUTANTI CyaA POLIPEPTIDI I POLIPEPTIDNI DERIVATI PRIKLADNI ZA DOPREMANJE IMUNOGENIÄŚNIH MOLEKULA U STANICU | |
| CN113874393B (zh) | 对hbv包膜蛋白具有特异性的结合分子 | |
| JP2019520336A5 (enExample) | ||
| FR2855971B1 (fr) | Analogues peptidiques comprenant au moins un residu aza-beta3-aminoacyle, et leurs utilisations, notamment en therapie | |
| US20240148877A1 (en) | Synthetic Strategy to Polymerize Protein into Molecularly Defined Polymers |